TransMedics Group (TMDX) Tops Q4 EPS by 3c, provides guidance

TransMedics Group (NASDAQ: TMDX) reported Q4 EPS of $0.19, $0.03 better than the analyst estimate of $0.16. Revenue for the quarter came in at $121.6 million versus the consensus estimate of $109.5 million.

GUIDANCE:

TransMedics Group sees FY 2025 revenue of $530-552 million, versus the consensus of $521.6 million.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Lockheed Martin wins $83 million Army missile contract
• Qualcomm (QCOM) PT Raised to $195 at BofA Securities